November 18, 2011 — The US Food and Drug Administration (FDA) announced today that it is rescinding its approval of bevacizumab (Avastin, Genentech) for treating metastatic breast cancer because the ...
September 26, 2006 — The US Food and Drug Administration (FDA) and Genentech, Inc, have notified healthcare professionals regarding safety labeling revisions for bevacizumab injection (Avastin) that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results